This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Dyslexia and other symbolic dysfunctions, not elsewhere classified
R18_DYSLE_OTHER_SYMBO_DYSFU_NOT_ELSEW_CLASSIFIED
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
146 |
4. Check minimum number of eventsNone |
146 |
5. Include endpointsNone |
146 |
6. Filter based on genotype QC (FinnGen only) |
143 |
Control definitions (FinnGen only)
- Control exclude
- R18_SYMPTOMS_SIGNS_INVOLVI_SPEECH_VOICE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- R4[7-9]
- Name in latin
- Dyslexia et aliae dysfunctiones discretionis symbolorum non alibi classificatae
Similar endpoints
↥List of similar endpoints to
Dyslexia and other symbolic dysfunctions, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Symptoms and signs involving speech and voice
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 143 | 79 | 64 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 55.51 | 50.77 | 61.35 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 146
- Matched controls
- 1460
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
R48.0
ICD-10 Finland
Dyslexia and alexia
+∞
75.8
66
*
R48.2
ICD-10 Finland
Apraxia
+∞
37.1
34
*
R48.8
ICD-10 Finland
Other and unspecified symbolic dysfunctions
+∞
25.8
24
*
R48
ICD-10 Finland
Dyslexia and other symbolic dysfunctions, not elsewhere classified
+∞
14.8
14
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
5.8
11.9
24
48
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.9
11.2
28
68
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
4.3
11.1
33
92
R48.1
ICD-10 Finland
Agnosia
+∞
10.5
10
*
R47.0
ICD-10 Finland
Dysphasia and aphasia
+∞
10.5
10
*
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
4.7
10.5
27
67
AA1AD
NOMESCO Finland
CT of head and brain
3.1
9.2
52
220
R53
ICD-10 Finland
Malaise and fatigue
3.0
9.0
54
236
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
4.4
8.8
24
62
N06AB10
ATC
escitalopram; oral
3.2
8.6
44
175
Z2445
NOMESCO Finland
Psychologist
8.4
8.5
18
24
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
4.1
8.0
24
67
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
6.5
7.5
19
33
R50.9
ICD-10 Finland
Fever, unspecified
3.2
7.2
33
122
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
7.1
41
173
N03AX12
ATC
[U] gabapentin; oral
3.2
7.0
32
118
Z71.9
ICD-10 Finland
Counselling, unspecified
4.4
6.9
18
45
N06AB04
ATC
citalopram; systemic
2.8
6.4
39
169
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
6.1
6.2
16
29
N03AX09
ATC
lamotrigine; oral
6.3
6.0
15
26
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
228
2.18
4.08
1.3
1.3
2.74
1.30
u/ml
0.47
14
56
6
5
12.43
3.79
1.2
1.6
1.98
1.89
mmol/l
—
6
5
42
236
2.09
3.71
4.7
3.8
1.02
1.01
kg/l
—
10
31
64
419
1.94
3.68
2.1
1.9
85.56
91.02
pmol/l
0.47
32
213
31
156
2.25
3.59
3.1
2.6
2.61
1.81
e6/l
0.26
17
94
14
54
2.76
2.79
2.9
3.3
0.05
0.12
e6/l
0.60
14
54
6
10
6.20
2.72
1.3
1.2
—
—
—
0
0
6
10
6.20
2.72
1.0
1.2
—
—
—
0
0
32
181
1.98
2.72
1.6
1.7
830.88
1177.46
nmol/l
2.31
26
141
8
19
4.39
2.72
1.6
1.9
—
—
—
0
0
55
372
1.77
2.69
4.0
3.1
—
—
—
0
0
69
498
1.73
2.68
7.5
7.8
1.21
1.22
mmol/l
0.39
64
416
6
11
5.63
2.57
1.0
1.2
—
—
—
0
0
6
12
5.16
2.42
1.0
1.2
—
—
—
0
0
67
492
1.67
2.37
13.9
11.9
1.23
1.27
inr
0.16
21
149
101
826
1.72
2.36
4.9
3.7
14.48
14.69
pmol/l
0.37
91
730
45
300
1.72
2.26
3.6
2.9
0.37
0.27
e6/l
0.15
35
231
117
1005
1.83
2.22
6.2
4.4
2.15
1.90
mu/l
0.26
108
903
80
627
1.61
2.11
9.4
9.6
4.42
4.21
e9/l
0.28
74
556
33
207
1.77
2.03
3.2
3.1
25.00
172.57
ng/l
1.01
19
156
27
161
1.83
1.96
2.9
2.5
0.64
0.95
e6/l
0.38
13
98
6
16
3.86
1.95
2.7
3.4
110.17
105.31
mmol/l
—
6
16
16
80
2.12
1.88
1.3
1.2
42.86
174.07
iu/ml
—
7
29
10
40
2.61
1.70
3.7
2.9
0.60
0.68
%
—
10
40
10
41
2.54
1.68
3.7
2.9
1.96
1.05
%
—
10
41
15
77
2.06
1.66
2.4
2.3
2.60
4.53
ug/l
0.93
15
65
13
63
2.17
1.65
1.2
1.0
—
—
—
0
0
15
80
1.98
1.51
4.2
4.1
2.40
2.35
mmol/l
0.03
15
65
35
244
1.57
1.44
1.9
2.1
—
—
—
0
0
29
193
1.63
1.44
1.3
1.3
14.00
30.67
iu/ml
—
5
64
11
53
2.16
1.42
5.0
4.5
137.64
128.17
g/l
1.16
11
53
70
569
1.44
1.37
6.1
5.9
13.17
10.58
umol/l
0.62
61
536
32
223
1.56
1.32
1.8
1.5
—
—
—
0
0
52
402
1.46
1.31
4.7
3.8
38.03
38.12
ng/l
0.00
41
265
97
842
1.45
1.30
8.1
6.8
75.32
74.62
u/l
0.06
91
774
67
545
1.42
1.28
4.7
3.7
0.00
0.00
estimate
-0.00
13
98
34
245
1.51
1.21
1.6
1.6
19.65
23.09
nmol/l
0.70
29
199
66
541
1.40
1.19
4.8
3.7
0.00
0.00
estimate
-0.00
14
109
39
291
1.46
1.17
4.8
3.9
0.00
0.01
estimate
0.50
13
97
8
40
2.06
1.14
4.8
4.3
27.10
25.20
mmol/l
—
8
40
61
501
1.37
1.06
2.5
2.7
—
—
—
0
0
5
22
2.32
1.04
1.2
1.3
—
—
—
0
0
5
22
2.32
1.04
1.2
1.3
—
—
—
0
0
12
68
1.83
1.04
2.4
3.8
153.14
67.77
ng/l
0.61
12
60
65
541
1.36
1.04
6.3
5.1
0.00
0.00
estimate
-0.00
13
104
26
184
1.50
1.00
1.2
1.3
4.05
8.08
u/ml
—
10
68
52
420
1.37
0.99
5.1
3.9
—
—
—
0
0
11
62
1.84
0.97
3.5
2.4
185.91
132.13
ng/l
0.32
11
55
120
1110
1.46
0.94
19.3
13.5
19.77
22.62
mg/l
0.54
102
861
55
454
1.34
0.90
2.5
2.2
71.24
74.62
nmol/l
0.41
50
394
8
43
1.91
0.89
6.4
3.7
47.35
45.65
%
—
8
43
6
31
1.97
0.85
1.2
1.3
—
—
—
0
0
21
152
1.45
0.74
2.5
3.3
0.84
0.83
mmol/l
0.18
21
143
5
25
2.03
0.73
1.4
1.3
—
—
—
0
0
28
218
1.35
0.67
1.4
1.7
412.91
444.66
pmol/l
0.25
22
187
7
44
1.62
0.66
1.1
1.6
—
—
—
0
0
14
197
0.68
0.64
1.1
1.4
—
—
—
0
0
112
1053
1.27
0.56
5.1
4.3
6.00
5.93
mmol/l
0.20
103
958
28
225
1.30
0.55
1.5
1.7
1.17
1.17
mg/l
0.00
22
178
80
728
1.22
0.53
3.7
2.9
45.11
43.72
u/l
0.08
75
680
106
993
1.25
0.53
6.3
5.4
40.36
39.63
mmol/mol
0.26
101
921
15
110
1.41
0.51
7.9
6.9
—
—
—
0
0
109
1026
1.25
0.51
17.4
12.5
84.15
83.52
ml/min/173m2
0.09
89
823
20
157
1.32
0.46
2.5
2.1
—
—
—
0
0
7
104
0.66
0.41
1.0
1.6
—
—
—
0
0
81
752
1.17
0.39
3.3
3.2
—
—
—
0
0
17
135
1.29
0.37
2.1
1.5
—
—
—
0
0
12
90
1.36
0.37
1.8
1.5
—
—
—
0
0
9
71
1.28
0.37
2.1
1.2
—
—
—
0
0
6
41
1.48
0.36
1.2
2.3
—
—
—
0
0
31
266
1.21
0.36
2.1
1.8
2.34
2.92
mg/l
1.53
23
227
19
229
0.80
0.33
5.8
4.0
22.54
20.67
%
—
8
109
18
147
1.26
0.32
2.2
1.9
—
—
—
0
0
17
138
1.26
0.32
2.1
1.6
—
—
—
0
0
7
96
0.72
0.32
1.1
1.6
—
—
—
0
0
10
75
1.36
0.31
8.2
3.3
52.40
64.58
ml/min/173m2
—
5
33
108
1036
1.16
0.30
4.3
3.6
1.26
1.26
mmol/l
0.03
100
942
114
1100
1.17
0.28
5.2
4.5
2.64
2.72
mmol/l
0.41
109
1002
5
39
1.29
0.23
1.2
2.0
—
—
—
0
0
5
41
1.23
0.22
1.6
1.4
—
—
—
0
0
33
298
1.14
0.22
4.3
3.5
6.71
10.01
mg/mmol
0.25
26
188
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
3.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
111
1079
1.12
0.19
4.7
4.0
1.41
1.46
mmol/l
0.61
105
987
111
1083
1.10
0.16
4.9
4.0
4.48
4.61
mmol/l
0.58
104
997
21
188
1.14
0.16
2.1
1.8
—
—
—
0
0
127
1251
1.12
0.12
27.8
19.3
249.05
249.10
e9/l
0.00
122
1214
127
1253
1.10
0.10
27.2
19.4
40.24
40.29
%
0.03
117
1166
5
43
1.17
0.10
1.0
3.6
24.58
25.03
mmol/l
—
5
43
5
47
1.07
0.09
1.0
2.2
32.16
40.91
u/l
—
5
40
5
61
0.81
0.08
1.2
1.4
—
—
—
0
0
120
1187
1.06
0.06
11.9
9.3
24.32
24.82
u/l
0.15
114
1136
10
106
0.94
0.01
5.8
3.4
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
0.00
0.0
1.0
—
125.60
—
0
5
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
0.00
0.0
1.0
—
149.60
—
0
5
0
5
0.00
0.00
0.0
1.4
—
6.48
—
0
5
0
5
0.00
0.00
0.0
1.0
—
98.40
—
0
5
0
7
0.00
0.00
0.0
1.3
—
14.43
—
0
7
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
113.00
—
0
5
8
89
0.89
-0.00
3.9
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
17.52
—
0
6
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
7
71
0.99
-0.00
4.3
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: R18_DYSLE_OTHER_SYMBO_DYSFU_NOT_ELSEW_CLASSIFIED – Dyslexia and other symbolic dysfunctions, not elsewhere classified
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).